The 4 analysts offering 12-month price forecasts for Aldeyra Therapeutics Inc have a median target of 26.00, with a high estimate of 33.00 and a low estimate of 15.00. The median estimate represents a +250.88% increase from the last price of 7.41.
The current consensus among 4 polled investment analysts is to Buy stock in Aldeyra Therapeutics Inc. This rating has held steady since September, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.28
Reporting Date Nov 11
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.